50th ASH Annual Meeting and Exposition (December 6 - 9, 2008): Myelodysplastic Syndromes: Clinical Studies: Genetic and Epigenetic Targets

Monday, December 8, 2008: 7:00 AM-9:00 AM

304-306-308 - South (Moscone Center)

Moderators:

Azra Raza, MD and Rena Buckstein, MD, FRCPC

7:00 AM

Final Results from a Phase I Combination Study of Lenalidomide and Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)

Mikkael A. Sekeres, MD, MS¹, Alan F. List, MD², David Cuthbertson³^*, Ronald Paquette, MD⁴, Deborah Latham, R.N.¹^*, Manual Afable, R.N.¹^*, Katarina Paulic¹^*, Thomas P. Loughran Jr., MD⁵ and Jaroslaw P. Maciejewski, MD, PhD⁶

¹Hematologic Oncology and Blood Disorders R35, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
²H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
³Pediatric Epidemiology Center, University of South Florida, Tampa, FL
⁴University of California, Los Angeles, Los Angeles, CA
⁵Penn State Cancer Institute - H072, Hershey, PA
⁶Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

7:15 AM

222

Oral (po) and Intravenous (iv) Clofarabine for Patients (pts) with Myelodysplastic Syndrome (MDS)

Stefan Faderl¹, Guillermo Garcia-Manero¹^*, Farhad Ravandi¹^*, Gautam Borthakur¹^*, Zeev Estrov¹^*, Deborah A. Thomas¹^*, Varsha Gandhi²^*, William Plunkett¹^*, Anna Byrd¹^*, Monica Kwari¹^* and Hagop M. Kantarjian¹^*

¹M.D. Anderson Cancer Center, Houston, TX
²U.T. M.D. Anderson Cancer Center, Houston, TX

7:30 AM

223

Maintenance Treatment with 5-Azacitidine for Patients with High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia Following MDS (MDS-AML) in Complete Remission (CR) after Induction Chemotherapy

Michael Grövdal¹, Rasheed Khan¹^*, Anni Aggerholm²^*, Petar Antunovic³^*, Jan Astermark⁴^*, Per Bernell⁵^*, Lena-Maria Engström⁶^*, Lars Kjeldsen⁷^*, Olle Linder⁸^*, Lars Nilsson⁹^*, Anna Olsson¹⁰^*, Jonas Wallvik¹¹^*, Jon Magnus Tangen¹²^*, Gunnar Öberg¹³^*, Sten Eirik Jacobsen⁹^*, Anna Porwit¹⁴^*, Peter Hokland² and Eva Hellström-Lindberg¹^*

¹Karolinska Institutet/Karolinska University Hospital Huddinge, Stockholm, Sweden
²Aarhus University Hospital, Aarhus, Denmark
³Linköping University Hospital, Linköping, Sweden
⁴Malmö University Hospital (MAS), Malmö, Sweden
⁵Karolinska University Hospital Solna, Stockholm, Sweden
⁶University Hospital of Norrland (NUS), Umeå, Sweden
⁷Rigshospitalet, Copenhagen, Denmark
⁸Örebro University Hospital, Örebro, Sweden
⁹Lund University Hospital, Lund, Sweden
¹⁰Sahlgrenska University Hospital, Gothenburg, Sweden
¹¹Sundsvall Hospital, Sundsvall, Sweden
¹²Ullevål University Hospital, Oslo, Sweden
¹³Uppsala Academic Hospital, Uppsala, Sweden
¹⁴Department of Pathology, Stockholm, Sweden

7:45 AM

224

Effect of Romiplostim in Patients (pts) with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Azacytidine

Hagop Kantarjian, MD¹^*, Frank Giles, MD²^*, Peter Greenberg, MD³, Ronald Paquette, MD⁴, Eunice Wang, MD⁵^*, Janice Gabrilove, MD⁶, Guillermo Garcia-Manero, MD¹, Julie Gray⁷^*, Kuolung Hu, PhD⁷^* and Janet Franklin, MD, MPH⁷

¹Leukemia Department, University of Texas MD Anderson Cancer Center, Houston, TX
²Cancer Therapy & Research Center, University of Texas Health Science Center, San Antonio, TX
³Stanford University Cancer Center, Stanford, CA
⁴University of California, Los Angeles, Los Angeles, CA
⁵Roswell Park Cancer Institute, Division of Hematologic Oncology, Buffalo, NY
⁶Mount Sinai School of Medicine, New York, NY
⁷Amgen Inc., Thousand Oaks, CA

8:00 AM

225

High Resolution Molecular Analysis of 5q- Syndrome Patients at Diagnosis and Following Lenalidomide Therapy

Azim M Mohamedali, PhD^*, Nicholas Lea, PhD^*, Natalie Twine, MSc^*, Joop Gaken, PhD^*, Rajani Chelliah, MSc^*, Nigel Westwood, PhD, CSci, FIBMS^* and Ghulam J Mufti, FRCP, FRCPath

Dept. of Haematological Medicine, Kings College London, London, United Kingdom

8:15 AM

226

Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study (06011) of the EORTC Leukemia and German MDS Study Groups

Pierre Wijermans¹, Stefan Suciu², Liliana Baila²^*, Uwe Platzbecker³, Aristoteles Giagounidis³, Dominik Selleslag³, Boris Labar³, Helmut Salih³, Filip Beeldens²^*, Petra Muus³, Theo de Witte³^* and Michael Lübbert, MD, PhD⁴^*

¹Dept of Hematology, Haga Hospital, The Hague, Netherlands
²EORTC Leukemia Group, Brussels, Belgium
³on behalf of EORTC or German MDS study Group
⁴Medical Center, University of Freiburg, Freiburg, Germany

8:30 AM

227

The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS)

Lewis R. Silverman, MD¹^*, Pierre Fenaux, MD, PhD²^*, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath³, Valeria Santini, MD⁴^*, Eva Hellström-Lindberg, MD, PhD⁵^*, Norbert Gattermann, MD⁶, Guillermo Sanz, MD, PhD⁷, Alan F. List, MD⁸, Steven D. Gore, MD⁹, John F Seymour, MBBS, PhD, FRACP¹⁰^*, Jay Backstrom, MD, MPH¹¹^*, David McKenzie, MS¹¹^* and C. L. Beach, PharmD¹¹^*

¹Division of Hematology, Mount Sinai School of Medicine, New York, NY
²Hôpital Avicenne/ Université Paris 13, Bobigny, France
³Department of Haematological Medicine, Kings College London, London, United Kingdom
⁴Hematology, Azienda Ospedaliera Careggi, Firenze, Italy
⁵Karolinska University Hospital, Stockholm, Sweden
⁶Heinrich-Heine-University, Düsseldorf, Germany
⁷Dept. of Hematology, Hospital Universitario La Fe, Valencia, Spain
⁸H Lee Moffitt Cancer Center and Research Institute, Tampa, FL
⁹The Sidney Kimmel Comprehensive Cancer Ctr. at Johns Hopkins, Baltimore, MD
¹⁰Dept of Haematology, Peter MacCallum Cancer Institute, Victoria, Australia
¹¹Celgene, Overland Park, KS

8:45 AM

228

Randomized Phase II Study of Combined Epigenetic Therapy: Decitabine Vs. Decitabine and Valproic Acid in MDS and AML

Jean-Pierre Issa¹, Ryan Castoro¹^*, Farhad Ravandi-Kashani¹^*, Stefan Faderl¹^*, Xuelin Huang¹^*, Elihu Estey²^*, Gautam Borthakur¹, Gail Morris¹^*, Guillermo Garcia-Manero¹^* and Hagop M Kantarjian¹^*

¹The University of Texas M. D. Anderson Cancer Center, Houston, TX
²University of Washington, Seattle, WA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

633.O1.8 Myelodysplastic Syndromes: Clinical Studies: Genetic and Epigenetic Targets